Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Issue 11 (19th September 2019)

• Record Type: Journal Article
• Authors: von Tresckow, Bastian; Fanale, Michelle; Ardeshna, Kirit M.; Chen, Robert; Meissner, Julia; Morschhauser, Franck; Moskowitz, Craig; Zinzani, Pier Luigi; Giezek, Hilde; Balakumaran, Arun; Vo, Thao T.; Raut, Monika; Brice, Pauline
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 11(2019)
• Page Start: 2705
• Page End: 2711
• Publication Date: 2019-09-19
• Subjects: Classical Hodgkin lymphoma -- health-related quality-of-life -- KEYNOTE-087 -- patient-reported outcomes -- pembrolizumab; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1602262
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) ( n = 69); (2) salvage chemotherapy and BV ( n = 79); and (3) ASCT without post-transplantation BV ( n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594.